Headquartered in 50 Broadway, London Fiscal year ends March NASDAQ: ROIV roivant.com
Roivant Sciences is a commercial-stage biopharmaceutical company that develops and commercializes medicines through focused subsidiaries it calls 'Vants'.
Its portfolio includes:
- **Priovant:** LISRAYA (brepocitinib), an oral JAK1/TYK2 inhibitor. It is FDA-approved for adult dermatomyositis and launched in the U.S. in August 2026. It is in late-stage development for non-infectious uveitis (sNDA planned for first half of 2027), cutaneous sarcoidosis and lichen planopilaris.
- **Immunovant:** IMVT-1402, a fully human anti-FcRn monoclonal antibody in development for IgG-mediated autoimmune diseases, including difficult-to-treat rheumatoid arthritis, Graves' disease, myasthenia gravis and CIDP.
- **Pulmovant:** mosliciguat, an inhaled sGC activator in Phase 3 for pulmonary hypertension associated with interstitial lung disease.
- **Genevant:** LNP delivery technology, which it monetizes through licensing and patent litigation, including a global settlement of up to $2.25 billion with Moderna.
Revenue currently comes from LISRAYA product sales plus license, milestone and other revenue. Updated
Roivant is a commercial-stage company now: LISRAYA pulled in $31.0 million of net product sales in just five weeks post-launch, beating expectations for almost no revenue at all. Management says the cash pile funds the company all the way to profitability.
Roivant Sciences is a commercial-stage biopharmaceutical company that develops and commercializes medicines through focused subsidiaries it calls 'Vants'. Its portfolio includes: - **Priovant:** LISRAYA (brepocitinib), an oral JAK1/TYK2 inhibitor.
24/7 Wall St.'s 12-month price target for ROIV is $56.50, rated Buy. The Wall Street consensus target is $50.00. ROIV price prediction →